Vivos Therapeutics Stock Current Liabilities
| VVOS Stock | USD 5.50 0.06 1.10% |
Fundamental analysis of Vivos Therapeutics allows traders to better anticipate movements in Vivos Therapeutics' stock price by examining its financial health and performance throughout various phases of its business cycle.
Total Current Liabilities is likely to gain to about 7.2 M in 2025, whereas Non Current Liabilities Total is likely to drop slightly above 1.8 M in 2025. Vivos | Current Liabilities | Build AI portfolio with Vivos Stock |
Vivos Therapeutics Company Current Liabilities Analysis
Vivos Therapeutics' Current Liabilities is the company's short term debt. This usually includes obligations that are due within the next 12 months or within one fiscal year. Current liabilities are very important in analyzing a company's financial health as it requires the company to convert some of its current assets into cash.
Vivos Current Liabilities Driver Correlations
Understanding the fundamental principles of building solid financial models for Vivos Therapeutics is extremely important. It helps to project a fair market value of Vivos Stock properly, considering its historical fundamentals such as Current Liabilities. Since Vivos Therapeutics' main accounts across its financial reports are all linked and dependent on each other, it is essential to analyze all possible correlations between related accounts. However, instead of reviewing all of Vivos Therapeutics' historical financial statements, investors can examine the correlated drivers to determine its overall health. This can be effectively done using a conventional correlation matrix of Vivos Therapeutics' interrelated accounts and indicators.
Click cells to compare fundamentals
Vivos Current Liabilities Historical Pattern
Today, most investors in Vivos Therapeutics Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Vivos Therapeutics' growth ratios. Consistent increases or drops in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's current liabilities growth rates may not be enough to decide which company is a better investment. That's why investors frequently use a static breakdown of Vivos Therapeutics current liabilities as a starting point in their analysis.
Vivos Therapeutics Current Liabilities |
| Timeline |
Current liabilities appear on the company's balance sheet and include all short term debt accounts, accounts and notes payable, accrued liabilities as well as current payments due on the long-term loans. One of the most useful applications of Current Liabilities is the current ratio which is defined as current assets divided by its current liabilities. High current ratios mean that current assets are more than sufficient to pay off current liabilities.
| Competition |
Vivos Total Current Liabilities
Total Current Liabilities |
|
In accordance with the recently published financial statements, Vivos Therapeutics has a Current Liabilities of 0.0. This is 100.0% lower than that of the Health Care Equipment & Supplies sector and 100.0% lower than that of the Health Care industry. The current liabilities for all United States stocks is 100.0% higher than that of the company.
Vivos Current Liabilities Peer Comparison
Stock peer comparison is one of the most widely used and accepted methods of equity analyses. It analyses Vivos Therapeutics' direct or indirect competition against its Current Liabilities to detect undervalued stocks with similar characteristics or determine the stocks which would be a good addition to a portfolio. Peer analysis of Vivos Therapeutics could also be used in its relative valuation, which is a method of valuing Vivos Therapeutics by comparing valuation metrics of similar companies.Vivos Therapeutics is currently under evaluation in current liabilities category among its peers.
Vivos Therapeutics Current Valuation Drivers
We derive many important indicators used in calculating different scores of Vivos Therapeutics from analyzing Vivos Therapeutics' financial statements. These drivers represent accounts that assess Vivos Therapeutics' ability to generate profits relative to its revenue, operating costs, and shareholders' equity. Below are some of Vivos Therapeutics' important valuation drivers and their relationship over time.
| 2020 | 2021 | 2022 | 2023 | 2024 | 2025 (projected) | ||
| Market Cap | 111.6M | 107.6M | 9.3M | 15.2M | 21.5M | 20.5M | |
| Enterprise Value | 114.8M | 90.7M | 8.1M | 15.5M | 16.8M | 15.9M |
Vivos Therapeutics ESG Sustainability
Some studies have found that companies with high sustainability scores are getting higher valuations than competitors with lower social-engagement activities. While most ESG disclosures are voluntary and do not directly affect the long term financial condition, Vivos Therapeutics' sustainability indicators can be used to identify proper investment strategies using environmental, social, and governance scores that are crucial to Vivos Therapeutics' managers, analysts, and investors.Environmental | Governance | Social |
Vivos Fundamentals
| Return On Equity | -4.5 | ||||
| Return On Asset | -0.61 | ||||
| Profit Margin | (0.77) % | ||||
| Operating Margin | (1.30) % | ||||
| Current Valuation | 31.45 M | ||||
| Shares Outstanding | 5.89 M | ||||
| Shares Owned By Insiders | 32.99 % | ||||
| Shares Owned By Institutions | 9.08 % | ||||
| Number Of Shares Shorted | 473.91 K | ||||
| Price To Book | 7.35 X | ||||
| Price To Sales | 2.21 X | ||||
| Revenue | 15.03 M | ||||
| Gross Profit | 8.59 M | ||||
| EBITDA | (10.55 M) | ||||
| Net Income | (11.14 M) | ||||
| Cash And Equivalents | 17.83 M | ||||
| Cash Per Share | 0.77 X | ||||
| Total Debt | 1.51 M | ||||
| Debt To Equity | 0.10 % | ||||
| Current Ratio | 3.15 X | ||||
| Book Value Per Share | 0.75 X | ||||
| Cash Flow From Operations | (12.69 M) | ||||
| Short Ratio | 2.04 X | ||||
| Earnings Per Share | (1.04) X | ||||
| Target Price | 4.22 | ||||
| Number Of Employees | 113 | ||||
| Beta | 6.98 | ||||
| Market Capitalization | 32.39 M | ||||
| Total Asset | 15.28 M | ||||
| Retained Earnings | (104.19 M) | ||||
| Working Capital | 2.5 M | ||||
| Net Asset | 15.28 M |
About Vivos Therapeutics Fundamental Analysis
The Macroaxis Fundamental Analysis modules help investors analyze Vivos Therapeutics's financials across various querterly and yearly statements, indicators and fundamental ratios. We help investors to determine the real value of Vivos Therapeutics using virtually all public information available. We use both quantitative as well as qualitative analysis to arrive at the intrinsic value of Vivos Therapeutics based on its fundamental data. In general, a quantitative approach, as applied to this company, focuses on analyzing financial statements comparatively, whereas a qaualitative method uses data that is important to a company's growth but cannot be measured and presented in a numerical way.
Please read more on our fundamental analysis page.
Thematic Opportunities
Explore Investment Opportunities
Additional Tools for Vivos Stock Analysis
When running Vivos Therapeutics' price analysis, check to measure Vivos Therapeutics' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Vivos Therapeutics is operating at the current time. Most of Vivos Therapeutics' value examination focuses on studying past and present price action to predict the probability of Vivos Therapeutics' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Vivos Therapeutics' price. Additionally, you may evaluate how the addition of Vivos Therapeutics to your portfolios can decrease your overall portfolio volatility.